This study assessed the effect of metronidazole on the gastroduodenal mucosa, intestinal permeability, blood loss, and inflammation in patients on non-steroidal anti-inflammatory drugs (NSAIDs). Thirteen patients were studied before and after 2-12 weeks' treatment with metronidazole 800 mg/day, while maintaining an unchanged NSAID intake. Intestinal inflammation, as assessed by the faecal excretion of indium-ill labelled neutrophils, and blood loss, assessed with chromium-51 labelled red cells, were significantly reduced after treatment (mean (SD) "'In excretion 4.7 (4.7)% v 1.5 (1.3)% (N<1-0%), p<0.001, 51Cr red cells loss 2.6 (1.6) ml/day v 0.9 (0.5) ml/day (N<1.0 mllday), p<001). Intestinal permeability assessed as the 5 hour urinary excretion ratio of 51CrEDTAIL-rhamnose did not change significantly (0.133 (0.046) v 0.154 (0.064), p>0O1) and there were no significant changes in the endoscopic or microscopic appearances of the gastroduodenal mucosa. These results suggest that the neutrophil is the main damaging effector cell in NSAID induced enteropathy. The main neutrophil chemoattractant in this enteropathy may be a metronidazole sensitive microbe.
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most successful group of drugs ever developed, with annual prescription rates in excess of 300 000 per million subjects in the western world.' 2 While this attests to their efficacy in reducing inflammation and pain, the treatment is not without side effects. The gastroduodenal mucosa is undoubtedly the main site of life threatening complications of NSAID treatment, manifesting as massive haemorrhage or perforation,3`6 and indeed NSAIDs may be an important cause of seemingly unexplained sudden deaths in the elderly.'
In the past few years it has become clear that the small intestine is also damaged by NSAIDs. In fact long term treatment causes small intestinal inflammation in 70% of patients. '°T he clinical importance of NSAID enteropathy lies in the associated complications of blood loss, protein loss, and occasional strictures that may require surgery." -" Although these complications are not usually life threatening, the consequent iron deficiency anaemia and hypoalbuminaemia (affecting 50% and 5-10% respectively of patients with rheumatoid arthritis) are major contributory factors to the morbidity of these patients.`'
The pathogenesis of NSAID enteropathy is unknown. It is suggested"`S that NSAIDs cause immediate cellular damage during drug absorption perhaps by uncoupling oxidative phosphorylation. This may result in loss of the integrity of the intercellular junctions which is evident as increased intestinal permeability to paracellular probe markers within 12 hours of NSAID ingestion in man.'9"After six months of NSAID treatment inflammation is evident. 9 It is suggested that the permeability changes allow mucosal exposure of luminal toxins (bile acids, pancreatic juices etc) and this paves the way for a bacterial invasion of the mucosa and hence the neutrophil chemotaxis." 11 X The participation of bacteria is further inferred from studies showing that pretreating animals with broad spectrum antibiotics before NSAID administration reduces the damage in the small intestine, and some studies show minimal damage in germ free animals.2' 26 During phagocytosis the neutrophils may cause tissue damage by oxygen free radical generation and lysosomal enzyme release and hence produce bleeding and protein loss."
The purpose of this study was to examine the effect of metronidazole on NSAID enteropathy in man. Intestinal permeability, inflammation, blood loss, and gastroduodenal morphology were assessed before and after metronidazole treatment in patients with established NSAID enteropathy.
Subjects and methods
Twenty patients who had been taking NSAIDs for more than six months underwent a screening phase and all 13 with NSAID enteropathy were recruited to the study. The clinical details of these patients are shown in Table I . Each subject was admitted to a metabolic research ward during these studies. On admission blood was taken for haematology and biochemistry and for leukocyte and red cell labelling. Intestinal permeability was assessed on day 6 and endoscopy was done on day 7 [tCi (15 MBq) "'1InCl3 (Amersham International, Amersham, Buckinghamshire, UK). Five ml of cell free plasma were then added to the cell suspension and centrifuged at 100 g for 5 minutes. The supernatant containing unlabelled 111In was poured off and the labelled cells were resuspended in 6.0 ml of cell free plasma. Five ml (9-12 MBq) were injected and the rest was used for standards. The labelling efficiency averaged 86% (range 79%-95%). The leukocytes maintain their integrity and function during the isolation and labelling procedure. Assuming a 300 [tCi (11 MBq) Samples were counted in a high resolution bulk sample counter as previously described.9 Standards (2% of the injected dose) were made up to 200 ml with water and distributed over a fixed amount offilter paper in a plastic container. Each sample was counted for 20 seconds, which enabled the measurement of 0.01% of the injected dose with a counting statistical accuracy of ±4%.
RED BLOOD CELL LABELLING"
When blood was obtained for labelling leukocytes, 10 ml were also placed in 20 ml sterile citrate/phosphate/dextrose solution. This suspension was centrifuged at 1500 g for 10 minutes. Sodium chromate (51Cr) (Amersham International) was added dropwise to the pellet, with continuous mixing, to a final activity of 55.5 kBq/kg body weight. This mixture was allowed to stand at room temperature for 15 minutes.
The labelled cells were washed twice in isotonic saline which leaves less than 1% of the 51Cr unbound. Ten ml labelled cells were injected into the patient. Daily blood samples were collected and 4 ml of every sample were used as counting standards. Faeces was collected for 5 days and the faecal 5 Cr activity was correlated with that of the blood standards from the previous day (which enables the calculation of blood loss into the intestine). The results are expressed as mean daily blood loss. The upper limit of normal for gastrointestinal blood loss is less than 1-0 ml/day. The estimated radiation dose from 55.5 kBq/kg body weight 51Cr-red cells is 1'2 mSv.
Because of the high initial "'In activity in the stools, it is necessary to delay counting of 5'Cr activity for 3 The day after the permeability test, patients on NSAIDs underwent gastroduodenoscopy (Olympus XQ20) with biopsy. Endoscopic damage was assessed by a modified Lanza score system.29 For the stomach, grades 0-3 had 0-2, 3-5, 6-10, and >10 erosions or submucosal haemorrhages respectively, and grade 4 had erosions or submucosal haemorrhages too numerous to be counted or an ulcer with clear disruption of the mucosal epithelium and a diameter greater than 0.5 cm. In the duodenum grade 0-3 had 0-1, 2-5,6-10, > 10 erosions, and grade 4 a duodenal ulcer.
Endoscopic biopsies (N:2) were taken from each of the following sites; the mid-greater curve of the body, the greater curve in the antrum at least 2 cm from the pylorus and from the duodenal bulb. They were routinely formalin fixed and paraffin processed. Sections (3 [tm) were cut and stained with haematoxylin and eosin, periodic -acid Schiff reagent/Alcian blue and Cresyl-fast violet, the latter to aid detection of Helicobacter pylori like organisms.
Gastritis 5 Cr red blood cell loss studies. Treatment with metronidazole caused a significant reduction in the mean daily blood loss from [2] [3] [4] [5] [6] (1[6) ml/day to 0 9 (0.5) ml/ day (p<001), (N<1 ml/day, mean (SD) 0-2 (0 1) ml/day). Figure 2 shows that there were no significant changes in the 5'CrEDTA/L-rhamnose urine excretion ratios during metronidazole treatment.
INTESTINAL PERMEABILITY
Ratios before and after treatment were 0d133 (0.046) and 0d154 (0.064) respectively (p>O 1), (N<0-09).
ENDOSCOPY AND HISTOLOGY
Ten patients underwent endoscopy with biopsy. Table II shows that endoscopic appearances did not change significantly during treatment. Ofthe 10 pairs of biopsy specimens taken from the body, antrum, and duodenum, the main abnormalities were found in the antrum. The antral specimens were normal in two, and three sets showed features typical of reactive (reflux) gastritis -a pattern associated with NSAID administration3' -before and after treatment.
In the remaining patients the severity of the chronic inflammatory infiltrate and activity was reduced by one grade between biopsies in three patients. There was an increase of one grade in two patients. H pylori like organisms were detected in two patients and persisted despite metronidazole. further supported by the findings that small intestinal permeability is not significantly affected by the treatment.
Collectively these data also suggest that the main site of NSAID induced blood loss in patients on long term NSAID treatment is the small intestine. Previous studies in man have shown a significant correlation between inflammatory activity (faecal excretion of 111In leukocytes) and 5'Cr red cell loss.'2 This is, however, the first study that also assesses gastroduodenal damage. The changes occurring in this limited biopsy series, in particular the inflammatory infiltrate, were on a minor scale and of no consistent pattern. They are unlikely to be the origin of the abnormalities shown by the labelling techniques. As the histological damage did not change in harmony with the inflammation and blood loss, it suggests that most of the chronic intestinal blood loss is from the small intestine. This is in keeping with large endoscopy studies showing that only rarely is there a gastroduodenal cause for positive faecal blood in patients on NSAIDs.394" Furthermore, small bowel enteroscopy in patients taking NSAIDs has confirmed the abnormalities in the mid small bowel, which range from erythematous blebs and villus atrophy to frank ulceration, all of which may bleed.4 Combined with reduced food intake and a high gastric pH, mild blood loss (1-8 ml/day) may be an important factor in the development of iron deficiency in patients with rheumatoid arthritis.'2 NSAID enteropathy and its complications contribute significantly to the overall morbidity of patients receiving these drugs. Metronidazole reduces intestinal inflammation and blood loss in NSAID enteropathy but the precise mechanism has not been established. Short courses of metronidazole may be indicated in patients with problematic iron deficiency anaemia or hypoalbuminaemia but long term treatment is clearly hampered by the possibility of peripheral neuropathy and other serious side effects of metronidazole.
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